TICKERNERD
Menu
TRDATRDAHealthcare · Biotechnology

TRDA Stock Forecast: Entrada Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$7.46
+0.13% on the day

The 8 Wall Street analysts covering Entrada Therapeutics, Inc. hold a median 12-month price target of $20 — +168.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$290.5M
Ticker Nerd rank
51 / 100
Median analyst target
$20
Analysts covering
8
Total return, dividends reinvested
1W
+8.6%
1M
+9.7%
YTD
−27.4%
1Y
+42.1%
From 52W high
−53.5%
From 52W low
+47.4%
$5
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TRDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Entrada Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
81
Volatility
77
Issuance
70
Size
63
Quality
49
Growth
39
Revisions
38
Momentum
37
Value
35

Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (35): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TRDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26TRDAHigh $25Median $20Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $11Median $20High $25

The green dot is the last close — the median target sits +168.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026GuggenheimMaintainsBuy$20 → $17
8 May 2026HC Wainwright & Co.DowngradeNeutral—
6 Apr 2026OppenheimerMaintainsOutperform—
18 Feb 2026HC Wainwright & Co.ReiteratesBuy—
11 Feb 2026GuggenheimInitiatesBuy—
20 May 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Feb 2025HC Wainwright & Co.ReiteratesBuy—
4 Feb 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024Roth MKMInitiatesBuy—
6 Nov 2024HC Wainwright & Co.MaintainsBuy—
6 Nov 2024OppenheimerMaintainsOutperform—
26 Aug 2024OppenheimerReiteratesOutperform—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—
25 June 2024HC Wainwright & Co.MaintainsBuy—
18 Mar 2024HC Wainwright & Co.ReiteratesBuy—
5 Jan 2024OppenheimerInitiatesOutperform—
27 Nov 2023HC Wainwright & Co.MaintainsBuy—
22 Sept 2023HC Wainwright & Co.ReiteratesBuy—
9 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TRDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
3
Fundamentals

Entrada Therapeutics, Inc. (TRDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
10.1×

Cheaper than 59% of US stocks

Price / sales
62.0×

Cheaper than 5% of US stocks

Price / book
1.0×

Cheaper than 74% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−53.9%

Higher than 5% of US stocks

Earnings growth (YoY)
−53.9%

Higher than 9% of US stocks

Gross margin
—
Operating margin
−5007.0%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−54.1%

Higher than 20% of US stocks

Return on assets
−29.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TRDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TRDAEntrada Therapeutics, Inc.$290.5M
51
SIONSionna Therapeutics, Inc.$288.3M
34
NMRANeumora Therapeutics, Inc.$291.3M
38
ELDNEledon Pharmaceuticals, Inc.$287.7M
32
IRDOpus Genetics, Inc.$293.8M
50
FULCFulcrum Therapeutics, Inc.$285.4M
33
TTRXTurn Therapeutics, Inc.$281.8M
16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Entrada Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRDA news & analysis

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

Entrada Therapeutics reported a Q2 loss of $1.01 per share, which was better than the Zacks Consensus Estimate of a $1.16 loss and slightly improved from the $1.04 per-share loss a year earlier. The company also topped revenue estimates for the quarter.

Why it matters — A TRDA watcher would care because the company beat analyst expectations on both loss per share and revenue, signaling performance ahead of what the market had forecast.

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 5 Aug 2026positive

Entrada Therapeutics reported its financial results for the second quarter ended June 30, 2026, and highlighted business updates, including expectations for multiple clinical data readouts. These include ELEVATE-44-201 Cohort 1 data by year-end 2026, Cohort 2 data in Q1 2027, ELEVATE-45-201 Cohort 1 data in October 2026, and Cohort 2 data in H1 2027, as well as Vertex's VX-670 Phase 1/2 data in DM1 in H2 2026.

Why it matters — TRDA watchers would care because the company has several scheduled clinical data readouts across 2026 and 2027 that could shape the outlook for its DMD and DM1 programs.

FAQ

Frequently asked questions about TRDA stock

What is the TRDA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Entrada Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $11 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRDA stock a buy right now?

Of the 8 analysts covering Entrada Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Entrada Therapeutics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRDA?

As at 15 Aug 2026, Entrada Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).

Will TRDA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +168.1% from the last close, and Ticker Nerd's factor model ranks Entrada Therapeutics, Inc. 51 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRDA stock forecast for 2030?

No analyst covering Entrada Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $25 over the next 12 months.

How has TRDA stock performed over the past year?

Entrada Therapeutics, Inc. returned +42.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Entrada Therapeutics, Inc. do?

Entrada Therapeutics Inc. is a biotechnology company focusing on the development of groundbreaking intracellular biologics.

What is the latest news on TRDA?

The most recent item we track (Zacks Investment Research, 5 Aug 2026): "Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates". Entrada Therapeutics reported a Q2 loss of $1.01 per share, which was better than the Zacks Consensus Estimate of a $1.16 loss and slightly improved from the $1.04 per-share loss a year earlier. The company also topped revenue estimates for the quarter.

Company

About Entrada Therapeutics, Inc.

Entrada Therapeutics Inc. is a biotechnology company focusing on the development of groundbreaking intracellular biologics. The company's core mission is to transform the treatment landscape for various diseases through innovative therapies that effectively cross cellular membranes to deliver potent biologics directly inside the cell. This approach has significant implications for a range of conditions, particularly those that are currently considered intractable with existing treatment modalities. The primary feature of Entrada's platform is its proprietary Endosomal Escape Vehicle (EEV) technology. This technology underpins the firm's efforts to develop biologics capable of intracellular delivery, thereby overcoming one of the major challenges in therapeutic development. It impacts sectors such as rare diseases, oncology, and other areas where treatment efficacy is hindered by the inability to efficiently deliver therapies inside cells. In the financial market, Entrada Therapeutics plays a crucial role as an innovator in drug development, attracting interest from investors and researchers who see potential in advancing treatment options. Its focus on intracellular biologics positions the company at the forefront of biotechnological advancement, contributing to ongoing transitions in how diseases can be managed at a molecular and cellular level.

CEO Mr. Dipal Doshi · 152 employees · United States · https://www.entradatx.com